The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients

NCT03960554 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Study lost funding

Conditions

Osteoporosis
Renal Osteodystrophy
Kidney Transplant; Complications

Interventions

DRUG: Denosumab Inj 60 mg/ml
OTHER: Placebo

Sponsor

Thomas Nickolas, MD MS